Explore recent issues of Contract Pharma covering key industry trends.
Read the full digital version of our magazine online.
Stay informed! Subscribe to Contract Pharma for industry news and analysis.
Get the latest updates and breaking news from the pharmaceutical and biopharmaceutical industry.
Discover the newest partnerships and collaborations within the pharma sector.
Keep track of key executive moves and promotions in the pharma and biopharma industry.
Updates on the latest clinical trials and regulatory filings.
Stay informed with the latest financial reports and updates in the pharma industry.
Expert Q&A sessions addressing crucial topics in the pharmaceutical and biopharmaceutical world.
In-depth articles and features covering critical industry developments.
Access exclusive industry insights, interviews, and in-depth analysis.
Insights and analysis from industry experts on current pharma issues.
A one-on-one video interview between our editorial teams and industry leaders.
Listen to expert discussions and interviews in pharma and biopharma.
A detailed look at the leading US players in the global pharmaceutical and BioPharmaceutical industry.
Browse companies involved in pharmaceutical manufacturing and services.
Comprehensive company profiles featuring overviews, key statistics, services, and contact details.
A comprehensive glossary of terms used in the pharmaceutical and biopharmaceutical industry.
Watch in-depth videos featuring industry insights and developments.
Download in-depth eBooks covering various aspects of the pharma industry.
Access detailed whitepapers offering analysis on industry topics.
View and download brochures from companies in the pharmaceutical sector.
Explore content sponsored by industry leaders, providing valuable insights.
Stay updated with the latest press releases from pharma and biopharma companies.
Explore top companies showcasing innovative pharma solutions.
Meet the leaders driving innovation and collaboration.
Engage with sessions and panels on pharma’s key trends.
Hear from experts shaping the pharmaceutical industry.
Join online webinars discussing critical industry topics and trends.
A comprehensive calendar of key industry events around the globe.
Live coverage and updates from major pharma and biopharma shows.
Find advertising opportunities to reach your target audience with Contract Pharma.
Review the editorial standards and guidelines for content published on our site.
Understand how Contract Pharma handles your personal data.
View the terms and conditions for using the Contract Pharma website.
What are you searching for?
Alliance expands in vitro oncology services
October 26, 2017
By: Kristin Brooks
Managing Editor, Contract Pharma
InSphero AG and Charles River Labs have entered a partnership under which Charles River will license its collection of patient-derived xenograft (PDX) tumors to InSphero, and Charles River will leverage InSphero’s 3D cell culture technology to extend its preclinical services using in vitro 3D InSight Tumor Microtissues derived from its existing PDX collection. In vitro 3D solutions enable the evaluation of a compound’s potency compared to standard-of-care drugs. This in vitro testing provides for identification of the promising drug candidates, tumor histotypes and molecular subtypes. Data collected in these tests can then be used to select PDX models for subsequent in vivo efficacy tests, as well as to run combination therapy studies over a range of concentrations and to correlate the tumor response with molecular data. “Over the past year, we have seen an increased demand from our oncology clients for enhanced speed and efficiency in early drug discovery,” said Birgit Girshick, corporate senior vice president, Global Discovery Services at Charles River. “In vitro discovery platforms offer a strong solution, and our partnership with InSphero significantly bolsters our capabilities in this field.” “Licensing Charles River’s robust library of PDX tumor models significantly expands our current disease model portfolio in diabetes and liver fibrosis,” said Jan Lichtenberg, Ph.D., chief executive officer and co-founder at InSphero. “The combination of their extensive background in PDX tumors, combined with our proprietary and industry-validated 3D cell culture technology, will help pave the way for future breakthroughs. Expanding our 3D InSight Discovery Platform to Charles River’s PDX models will offer scalability, speed and unmet biological relevance in vitro.”
Enter your account email.
A verification code was sent to your email, Enter the 6-digit code sent to your mail.
Didn't get the code? Check your spam folder or resend code
Set a new password for signing in and accessing your data.
Your Password has been Updated !